Back to today’s briefing

Story perspectives

Breakthrough Therapy Shows Survival Gains in Breast Cancer Trial

10/6/2025

48 5 Full Breakdown

Summary

Story summary

Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo showed OS and PFS gains in metastatic triple-negative breast cancer in TROPION-Breast02 trial, targeting the TROP2 protein.
It is the first therapy to show OS benefit versus chemotherapy for patients unable to receive immunotherapy.
The 644-patient trial met dual primary endpoints, and safety aligned with prior studies.

1 of 1

Story summary

Datroway (datopotamab deruxtecan) from AstraZeneca and Daiichi Sankyo showed OS and PFS gains in metastatic triple-negative breast cancer in TROPION-Breast02 trial, targeting the TROP2 protein.
It is the first therapy to show OS benefit versus chemotherapy for patients unable to receive immunotherapy.
The 644-patient trial met dual primary endpoints, and safety aligned with prior studies.